@entity66 is the first predictive factor for survival in @entity1 with @entity43 . Neoadjuvant chemotherapy still has not proved superiority in terms of overall survival compared with complete initial resection. Hence, initial surgery remains the cornerstone of management for @entity1 with advanced @entity43 . Various parameters have been proposed to evaluate the ability of complete resection. Clinical evaluation of peritoneal @entity189 and @entity843 is not relevant enough while general status (ASA score) is correlated with the risk of @entity260 . Preoperative dosage of @entity10224 higher than 500 UI/L seems to be related with an increase risk of sub-optimal surgery. Recently, some authors challenged its prognostic value. For a @entity10224 threshold at 500 UI/L, sensitivity, specificity, positive and negative predictive values range from 58 to 78%, 64 to 89%, 64 to 84% and 35.7 to 85.4%, respectively. Imaging criteria failed to report concordant results. Indeed, sensitivity, specificity, positive and negative predictive values vary from 52 to 100%, 75 to 100%, 49% to 100% and 50 to 100%, respectively. High-correlation has been demonstrated for @entity189 scores evaluating the dissemination of the disease (AUCs of ROCs curves higher than 0.6). At laparotomy, for an Eisenkop score under 6, 99% of @entity1 could benefit of complete resection. At laparoscopy, for a Fagotti score under 4, a complete cytoreduction could be obtained in 78% of @entity1 . This score had the best AUC (0.76). Various scoring systems are available for surgeons to evaluate the resecability of advanced @entity43 . Among them, peroperative scoring systems appear the best tool and should be recommended in routine especially at first laparoscopy. Finally, due to the impact on survival of complete initial resection, @entity1 with advanced @entity43 should be referred to specialized centres.

[Advanced XXXX : criteria of resectability].

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Residual disease'] @entity843 :: ('MESH:D001201', 'Disease') :: ['ascite'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomatosis'] @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications'] @entity10224 :: ('94025', 'Gene') :: ['CA-125']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
